Growth investment in new products, M&A and business alliances
First written in FY2016. 7 of 20 entries say "Restated". Latest entry: 2026-05-14.
The whole theme swung hardest in 2020: 3 of 22 companies on the "Worse" side.
12 other companies' latest entry also says "Advanced".
- 2026-05-14AdvancedManagement Planning
「Actively pursue business alliances and M&A」
既存事業と周辺事業領域の強化・拡大を目的に、事業提携・M&Aを積極推進する方針を明示した。 - FY2026-H1RestatedAnnual report
「None.」
There were no applicable important contracts or other matters during the interim consolidated accounting period, and no progress on new contracts relating to M&A, business alliances or other matters was disclosed. - FY2024-Q3RestatedAnnual report
「During the third quarter consolidated accounting period under review, there were no decisions to enter into, or executions of, material contracts or other agreements relating to management.」
The company reconfirmed that no important contracts relating to M&A, business alliances or other matters were signed during the quarter. - FY2024-Q2RestatedAnnual report
「During the second quarter of the consolidated fiscal year, there were no decisions or agreements concerning material business contracts.」
The company reconfirmed that no important contracts relating to M&A, business alliances or other matters were signed during the quarter. - FY2024-Q1AdvancedAnnual report
「Although the company continued to revise selling prices in response to the substantial increase in raw material and fuel prices from the previous fiscal year, revenue for the cumulative period was ¥8.746 billion, down 25.9% year on year, because Alkaline S.A.S., formerly a consolidated subsidiary, was excluded from consolidation following the transfer of all its shares.」
For Alkaline, which was at the agreement-signing stage in the previous filing, the exclusion from consolidation following the transfer of all shares was reflected in the results. Concrete progress in streamlining the business portfolio was confirmed. - FY2023-Q3ReframedAnnual report
「The group formulated the long-term management vision “Kagaku de, Kagayaku. 2030” and the three-year medium-term management plan “Kagaku de, Kagayaku. Stage I” (fiscal years ending March 2021 to March 2023), and is pursuing initiatives to build a robust business base. Under the plan, the group aims to transform its business portfolio into one that is resilient to changes in the business environment and generates stable earnings by increasing the allocation of resources toward expanding high-value-added businesses and thoroughly improving management efficiency. As part of these initiatives, it signed a share transfer agreement relating to this share transfer.」
In addition to the previous trend of growth investment and acquisitions, the sale of Alkaline indicated a streamlining of the business portfolio, broadening and reshaping the role of M&A. - FY2022ReframedAnnual report
「March 2022: Certis Europe B.V. was removed from the scope of equity-method affiliates because the company’s ownership percentage declined.」
Certis Europe B.V.’s relationship changed from growth investment and a partnership as an equity-method affiliate to exclusion from the equity method due to the decline in the ownership percentage. A ¥1.760 billion gain on the exchange of shares in an affiliated company was also recorded. - FY2022-Q2RestatedAnnual report
「During the second quarter of the consolidated fiscal year, there were no decisions or agreements concerning material business contracts.」
The company reiterated that no important contracts relating to M&A, business alliances or other matters were signed during the quarter. - FY2021-Q3RestatedAnnual report
「There were no decisions or agreements concerning important management-related contracts or other matters during the consolidated third-quarter accounting period.」
The company stated that no important contracts relating to M&A, business alliances or other matters were signed in the third quarter either. - FY2021-Q2RestatedAnnual report
「There were no decisions or agreements concerning important management-related contracts or other matters during the consolidated second-quarter accounting period.」
The company stated that no important contracts relating to M&A, business alliances or other matters were signed in the second quarter. - FY2020No progress on M&A or business alliancesAnnual report
「Due in part to the lack of progress on the M&A and business alliances incorporated into the plan, and to investment income accounted for under the equity method remaining below plan, the operating margin was 5.6%, ordinary income was ¥10.312 billion and ROE was 4.8%.」
The company stated that there had been no progress by the final year of the medium-term management plan on the M&A and business alliances incorporated into the plan. - FY2019Cited as achievedAnnual report
「The acquisition of Zoetis Japan’s Plant Health business, comprising the insecticide “Gringuard” and fungicide “Agrimycin,” was completed and contributed to earnings.」
The company reported the contribution to earnings during the fiscal year from the acquisition of Zoetis Japan’s Plant Health business, which had been completed in the previous fiscal year. - FY2019-Q2AchievedAnnual report
「The acquisition of Zoetis Japan’s Plant Health business was completed on 14 September of this year.」
The acquisition of Zoetis Japan’s Plant Health business, which had been scheduled in the previous filing, was completed on 14 September 2018. The consideration was stated to be ¥5.229 billion in cash. - FY2019-Q1SoftenedAnnual report
「3. Timing of business acquisition: August 2018 (scheduled). The timing of the acquisition may be changed.」
The scheduled timing for acquiring Zoetis Japan’s Plant Health business changed from July 2018, as stated in the previous filing, to August 2018, with an additional note that the timing may change. - FY2018RestatedAnnual report
「Through this acquisition, the group will obtain the leading domestic market share in pine wilt disease control products, expand its agricultural chemicals product portfolio and is expected to generate synergies with existing products. The company decided to make the acquisition after determining that strengthening its business base in these ways would contribute to further increasing the group’s corporate value.」
The company explained the significance of acquiring Zoetis Japan’s Plant Health business, including obtaining the leading domestic market share, expanding the product portfolio and generating synergies with existing products. The acquisition was scheduled for July 2018, and completion had not yet been disclosed. - FY2018-Q3AdvancedAnnual report
「On 30 November 2017, the company signed an agreement with Zoetis Japan K.K. for the acquisition of Zoetis Japan’s Plant Health business.」
As a concrete growth investment through M&A and a business alliance, the company signed an agreement on 30 November 2017 to acquire Zoetis Japan’s Plant Health business, which handles forest pest-control and agricultural chemicals. The acquisition was scheduled for late March 2018. - FY2017AdvancedAnnual report
「The targets set out in the “New Medium-Term Management Plan (FY2017-FY2019)” are an operating margin of at least 6.5% (at least 8.0% excluding the trading business), ordinary income of ¥13.0 billion for the fiscal year ending March 2020, ROE of at least 7.0%, and total investment of ¥50.0 billion over 3 years (¥10.0 billion in growth investment, ¥20.0 billion in maintenance and renewal investment, and ¥20.0 billion in M&A and other investment).」
The new medium-term management plan specified a ¥50.0 billion three-year investment framework for growth investment, maintenance and renewal investment, M&A and other uses. The planned position of growth investment following the additional acquisition of Certis became clear. - FY2017-Q3AdvancedAnnual report
「At a meeting of the Board of Directors held on 9 December 2016, the company resolved to enter into an agreement primarily involving the transfer to it of 147 shares of Certis Europe B.V. and an agreement primarily involving the transfer to it of 442 shares of Certis. The share transfer agreements were signed on 20 December 2016.」
The company signed share transfer agreements with Certis, making concrete progress on the business alliance and growth investment relating to its European operations. - FY2017-Q3AdvancedAnnual report
「Following this acquisition of shares, the company will position Certis as an important partner in Europe, expand sales of its products and rapidly increase the market share of new agricultural chemicals scheduled for launch.」
As a concrete example of growth investment and a business alliance, Certis became an equity-method affiliate, and the company entered the stage of expanding sales in Europe and increasing the market share of new agricultural chemicals. - FY2016First statedAnnual report
「The company will give top priority to accelerating the development and early launch of new products, as well as growth investments such as M&A and business alliances, while also making maintenance and renewal investments that contribute to stable and sustainable growth.」
The company says it will prioritize the early launch of new products, M&A and business alliances as avenues for growth investment.